2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
The application claims a compound of the formula or a salt, a hydrate, or a hydrate of a salt thereof. The compounds inhibit cGMP-metabolizing phosphodiesterases and are suitable for use as active compounds in pharmaceuticals, for the treatment of erectile dysfunction.
1. A compound of the formula:
or a salt, a hydrate, or a hydrate of a salt thereof.
2. The compound according to claim 1 having the chemical name 2-[2-ethoxy-5-(4-ethyl-piperazine-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one hydrochloride.
3. The compound according to claim 1 having the chemical name 2-[2-ethoxy-5-(4-ethyl-piperazine-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one hydrochloride trihydrate.
4. A pharmaceutical composition comprising a compound according to claim 1 and a pharmacologically acceptable formulating agent.
5. A method of treating erectile dysfunction comprising administering to a mammal an effective amount of a compound according to claim 1 .
6. The method of treating erectile dysfunction according to claim 5 wherein the mammal is a human.